Vaxxass is a biotechnology company focused on needle-free vaccination technology.
Vaxxass is a biotechnology company that develops a novel needle-free vaccination technology. The company uses proprietary dry-coating technology that can eliminate or significantly reduce the need for vaccine refrigeration during storage and transportation - easing the resource and logistics burden of maintaining the vaccine "cold chain". Vaxxas was incorporated in 2011 and is based in Brisbane, Australia.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 5, 2022 | Series C | $34M | 2 | OneVentures UniQuest, | — | Detail |
Sep 20, 2022 | Grant | $8.20M | 1 | Australian Government | — | Detail |
Jan 1, 2021 | Grant | $4.40M | 1 | Australian Government | — | Detail |
Oct 5, 2020 | Grant | $22M | 1 | Biomedical Advanced Research and Development Authority (BARDA) | — | Detail |
Mar 17, 2020 | Grant | $5M | 1 | Bill & Melinda Gates Foundation | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
OneVentures | Yes | Series C |
UniQuest, | Yes | Series C |
Australian Government | Yes | Grant |
Biomedical Advanced Research and Development Authority (BARDA) | Yes | Grant |
Bill & Melinda Gates Foundation | Yes | Grant |
HealthCare Ventures | — | Series B |
Brandon Capital Partners | — | Series A |
Medical Research Commercialisation Fund (MRCF) | — | Series A |